None

Tofacitinib Delay May Give FDA Time To Look At New Radiographic Data

FDA has extended the review deadline to look over requested data on tofacitinib, but Pfizer is also interested in turning over an interim analysis of the ORAL Start study, which provides radiographic...

Pfizer Hopes Tofacitinib Delay Will Give FDA Time To Look At New Radiographic Data

FDA has extended the review deadline to look over requested data on tofacitinib, but Pfizer is also interested in turning over an interim analysis of the ORAL Start study, which provides radiographic...

Pfizer announces positive top-line results from the ORAL Start Phase 3 study of Tofacitinib in RA

Pfizer also provides update on Tofacitinib filing in the U.S.

Pfizer announces data for investigational compound tofacitinib in rheumatoid arthritis to be presented at the ACR 2012 Annual Meeting

14 abstracts for tofacitinib...

RA Oral Therapy: Tofacitinib Promising in 2 Studies

One study suggests tofacitinib may be as effective as a TNF-blocker for rheumatoid arthritis. Medscape Medical News

FDA approves tofacitinib for RA

FDA approved an NDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib to treat moderate to severe rheumatoid arthritis in adults with an inadequate response or intolerance to methotrexate. Xeljanz m...

Newly approved tofacitinib slows rheumatoid arthritis joint damage

A Phase III clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (M...

Pfizer’s RA pill impresses in Phase III

Pfizer’s investigational arthritis drug tofacitinib has beaten methotrexate in a head-to-head study. Tofacitinib, an oral Janus kinase (JAK) inhibitor, is seeking a licence for the treatment of adul...

Tofacitinib in Active Ulcerative Colitis.

To the Editor: Sandborn et al. (Aug. 16 issue)(1) report that tofacitinib has efficacy in the treatment of ulcerative colitis. The authors note that Janus kinase (JAK) inhibitors JAK1 and JAK3 are sur...

Tofacitinib in Active Ulcerative Colitis.

To the Editor: Sandborn et al. (Aug. 16 issue)(1) report that tofacitinib has efficacy in the treatment of ulcerative colitis. The authors note that Janus kinase (JAK) inhibitors JAK1 and JAK3 are sur...

Tofacitinib in Active Ulcerative Colitis.

To the Editor: Sandborn et al. (Aug. 16 issue)(1) report that tofacitinib has efficacy in the treatment of ulcerative colitis. The authors note that Janus kinase (JAK) inhibitors JAK1 and JAK3 are sur...

Lack of Effect of Tofacitinib (Cp 690,550) on The Pharmacokinetics of Cyp3a4 Substrate Midazolam in Healthy Volunteers: Confirmation of in Vitro Data.

Aims:  To investigate inhibitive and inductive effects of tofacitinib (CP-690,550), a Janus kinase inhibitor, on CYP3A4 function via in vitro and in vivo studies. Methods:  In vitro experiments we...

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.

Rheumatoid arthritis (RA) is a representative autoimmune disease characterized by chronic and destructive inflammatory synovitis. The multiple cytokines play pivotal roles in RA pathogenesis by induci...